For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240507:nRSG2538Na&default-theme=true
RNS Number : 2538N Tristel PLC 07 May 2024
Tristel plc
("Tristel" or the "Company")
Exercise of Share Options and Total Voting Rights
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products,
announces that it has issued and allotted a total of 11,500 new ordinary
shares of 1 penny each in the capital of the Company ("Ordinary Shares")
following the exercise of options by employees of the Group.
Application has been made to the London Stock Exchange for the 11,500 new
Ordinary Shares to be admitted to trading on AIM ("Admission") and it is
expected that Admission will become effective and trading will commence at
8.00 a.m. on 13 May 2024.
Total Voting Rights
After Admission, the total number of Ordinary Shares in issue will be
47,536,493 and the total number of voting rights will therefore be 47,536,493.
This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of the
Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information please contact:
Tristel plc Tel: 01638 721 500
Paul Swinney, Chief Executive Officer
Liz Dixon, Chief Financial Officer
Walbrook PR Ltd Tel: 020 7933 8780 or tristel@walbrookpr.com
Paul McManus Mob: 07980 541 893
Alice Woodings Mob: 07407 804 654
Charlotte Edgar Mob: 07884 664 686
Cavendish Capital Markets Limited Tel: 020 7220 0500
Geoff Nash/Charlie Beeson (Corporate Finance)
Sunila de Silva (ECM)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IOEAJMATMTIMBAI